

## Genome-wide association analysis reveals extensive genetic overlap between mood instability and psychiatric disorders but divergent patterns of genetic effects

Guy Hindley (M.B.B.S.)<sup>1,2\*</sup>, Kevin S. O’Connell (Ph.D.)<sup>1</sup>, Zillur Rahman (Ph.D.)<sup>1</sup>, Oleksandr Frei (Ph.D.)<sup>1,3</sup>, Shahram Bahrami (Ph.D.)<sup>1</sup>, Alexey Shadrin (Ph.D.)<sup>1</sup>, Margrethe Collier Høegh (M.Sc.)<sup>1</sup>, Weiqiu Cheng (Ph.D.)<sup>1</sup>, Naz Karadag (M.Sc.)<sup>1</sup>, Aihua Lin (PhD)<sup>1</sup>, Linn Røddevand (Cand.psychol)<sup>1</sup>, Chun C. Fan (M.D.)<sup>4, 5, 6</sup>, Srdjan Djurovic (Ph.D.)<sup>7,8,9</sup>, Trine Vik Lagerberg (Ph.D.)<sup>1</sup>, Anders M. Dale (Ph.D.)<sup>4,5,10,11</sup>, Olav B. Smeland (M.D.)<sup>1</sup>, Ole A. Andreassen (M.D.)<sup>1,9\*</sup>

<sup>1</sup>NORMENT Centre, Institute of Clinical Medicine, University of Oslo and Division of Mental Health and Addiction, Oslo University Hospital, 0407 Oslo, Norway;

<sup>2</sup>Psychosis Studies, Institute of Psychiatry, Psychology and Neurosciences, King’s College London, 16 De Crespigny Park, London SE5 8AB, United Kingdom

<sup>3</sup>Center for Bioinformatics, Department of Informatics, University of Oslo, PO box 1080, Blindern, 0316 Oslo, Norway, <sup>4</sup>Department of Radiology, University of California, San Diego, La Jolla, CA 92093, United States of America; <sup>5</sup>Multimodal Imaging Laboratory, University of California San Diego, La Jolla, CA 92093, United States of America; <sup>6</sup>Department of Cognitive Science, University of California, San Diego, La Jolla, CA, USA; <sup>7</sup>Department of Medical Genetics, Oslo University Hospital, Oslo, Norway; <sup>8</sup>NORMENT Centre, Department of Clinical Science, University of Bergen, Bergen, Norway; <sup>9</sup>KG Jebsen Centre for Neurodevelopmental disorders, University of Oslo, Oslo, Norway, <sup>10</sup>Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA, <sup>11</sup>Department of Neurosciences, University of California San Diego, La Jolla, CA 92093, United States of America.

### ABSTRACT

Mood instability (MOOD) is a transdiagnostic phenomenon with a prominent neurobiological basis. Recent genome-wide association studies found significant positive genetic correlation between MOOD and major depression (DEP) and weak correlations with other psychiatric disorders. We investigated the polygenic overlap between MOOD and psychiatric disorders beyond genetic correlation to better characterize putative shared genetic determinants. Summary statistics for schizophrenia (SCZ, n=105,318), bipolar disorder (BIP, n=413,466), DEP (n=450,619), attention-deficit hyperactivity disorder (ADHD, n=53,293) and MOOD (n=363,705), were analysed using the bivariate causal mixture model and conjunctive false discovery rate methods to estimate the proportion of shared variants influencing MOOD and each disorder, and identify jointly associated genomic loci. MOOD correlated positively with all psychiatric disorders, but with wide variation in strength ( $r_s=0.10-0.62$ ). Of 10.4K genomic variants influencing MOOD, 4K-9.4K were estimated to influence psychiatric disorders. MOOD was jointly associated with DEP at 163 loci, SCZ at 110, BIP at 60 and ADHD at 25, with consistent genetic effects in independent samples. Fifty-three jointly associated loci were overlapping across two or more disorders (transdiagnostic), seven of which had discordant effect directions on psychiatric disorders. Genes mapped to loci associated with MOOD and all four disorders were enriched in a single gene-set, “synapse organization”. The extensive polygenic overlap indicates shared molecular underpinnings across MOOD and psychiatric disorders. However, distinct patterns of genetic correlation and effect directions of shared loci suggest divergent effects on corresponding neurobiological mechanisms which may relate to differences in the core clinical features of each disorder.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## INTRODUCTION

Mood instability (MOOD) is a psychological construct defined as a tendency to experience frequent, rapid fluctuations of intense affect and an inability to regulate these fluctuations or their behavioural sequelae (1). The concept was first described in people with borderline personality disorder and is a central component of the disorder (2). While present in approximately 14% of the general population (3), it is also overrepresented in several other psychiatric disorders, including schizophrenia (SCZ), bipolar disorder (BIP), depression (DEP), and attention-deficit hyperactivity disorder (ADHD) (4–7). Furthermore, MOOD is a predictor and trait-marker for both DEP and BIP (6,8–10), and is associated with suicidality and poor treatment outcomes in multiple disorders (4,11).

There is mounting evidence supporting a prominent neurobiological basis to MOOD. Firstly, twin studies have estimated 25% and 40% heritability for affect intensity and affective lability respectively, central components of MOOD (12). Secondly, symptoms mirroring MOOD can be caused by seizure activity or localised brain lesions, typically involving the pre-frontal cortex, the temporal lobe and the diencephalon (13). Thirdly, neuroimaging, behavioural, cognitive and electrophysiological studies have reported an array of neurobiological correlates, of which alterations in amygdala activation and connectivity between the ventromedial prefrontal cortex, amygdala and anterior cingulate cortex are the most convincing (14). In combination with its clinical significance, MOOD therefore represents a promising transdiagnostic therapeutic target that could be leveraged to develop novel treatments and inform personalized psychiatric treatment, consistent with the Research Domain Criteria framework (15). Despite this, questions remain over MOOD's neurobiological and phenomenological consistency across and within diagnostic groups, particularly in disorders such as SCZ, which is classically associated with reduced affective expression despite increased MOOD (2,16).

An improved understanding of the shared genetic basis of MOOD and different psychiatric disorders may provide insights into these questions. Two large-scale GWASs of MOOD in the UK Biobank have previously identified 46 genomic loci and strong positive genetic correlations with depression, but weak positive correlations with SCZ, BIP and ADHD (17,18). This has implicated several genes in MOOD

which are also implicated in psychiatric disorders, including *PLCL1* in SCZ, *PLCL2* in BIP and *NEGR1* in DEP (18–21). Nonetheless, much of the genetic basis for MOOD and psychiatric disorders remains unexplained and individual loci linked to both have yet to be examined systematically (18,22). Furthermore, the identification of overlapping loci might help to disentangle the effects of different risk loci on the diverse phenomenology of psychiatric disorders and highlight neurobiological pathways with therapeutic potential (15).

To this end, we applied state-of-the-art statistical tools to summary statistics from GWAS of MOOD, SCZ, BIP, DEP and ADHD (18–21,23). We first used the bivariate causal mixture model (MiXeR) to estimate the total number of trait-influencing variants shared between MOOD and psychiatric disorders (24). Since MiXeR quantifies total genetic overlap and is unable to identify shared genomic loci, we next employed the conjunctive false discovery rate (conjFDR) method to discover loci jointly associated with MOOD and each psychiatric disorder beyond genome-wide significance (25). Unlike genetic correlation, which provides an aggregate measure for the balance of variants with concordant and discordant effects on two phenotypes, MiXeR and conjFDR are able to identify genetic overlap regardless of effect direction (26). These methods complement genetic correlation to provide a more comprehensive overview of the genetic relationships between phenotypes. Given MOOD's increased prevalence across multiple diagnostic categories, we also aimed to identify loci that were common to MOOD and more than one psychiatric disorder, representing “transdiagnostic” MOOD loci. Finally, the conjFDR method also leverages cross-phenotype enrichment to boost the power to identify novel genomic loci for each phenotype, thus contributing to efforts to unravel the “missing” heritability of psychiatric disorders (22,25).

## METHODS AND MATERIALS

### Samples

We acquired summary statistics from a GWAS of MOOD in the UK Biobank (n=363,705) (18). MOOD was assessed by a yes/no questionnaire item “does your mood often go up and down?” (18). While this only captures “frequent fluctuations of affect” and no other features of MOOD, e.g. affect intensity (1), a positive response has been found to be 2.5 and 14.3 times more prevalent in people with DEP and BIP compared to controls, demonstrating its clinical relevance (8). The SCZ sample comprised a meta-analysis of CLOZUK and Psychiatric Genomics Consortium (PGC) consisting of 40,675 cases and 64,643 controls (19). The DEP sample was a meta-analysis of PGC and 23andMe, Inc. samples comprising a total of 121,198 cases and 329,421 controls (21). BIP and ADHD samples were acquired from the latest PGC GWAS, comprising 41,917 cases and 371,549 controls for BIP (27) and 19,099 cases and 34,194 controls for ADHD (23). All samples were of European descent. We also included height as a non-psychiatric comparator (n=709,706) (28). The PGC East Asian SCZ sample (cases = 22,778, controls = 35,362) (29) and FinnGenn BIP (cases = 4,501, controls = 192,220) and DEP (cases = 17,794, controls = 156,611) samples (30) were used for replication (*Supplementary methods*). The Norwegian Institutional Review Board: Regional Committees for Medical and Health Research Ethics (REC) South-East Norway evaluated the current protocol and found that no additional ethical approval was required because no individual data were used.

### Data analysis

MiXeR v1.3 was applied to MOOD and each of SCZ, BIP, DEP, ADHD, and height (24). MiXeR first uses a univariate gaussian mixture model to quantify the polygenicity of each trait from GWAS summary statistics, expressed as the number of ‘trait-influencing’ variants (also referred to as ‘causal’ variants). Next, a bivariate gaussian mixture model is constructed to quantify the additive genetic effect of four components: 1) variants not influencing either phenotype; variants uniquely influencing either the 2) first or 3) second phenotype and 4) variants influencing both phenotypes. Results are visualised as a Venn diagram. MiXeR also calculates the genetic correlation between phenotypes and predicts the

proportion of shared variants with concordant effect direction on both phenotypes. Estimates and standard errors are calculated by performing 20 iterations using 2 million randomly selected SNPs for each iteration, followed by random pruning at an linkage disequilibrium threshold of  $r^2=0.8$ . Model fit is based on likelihood maximization of signed test statistics (GWAS z-scores), evaluated by the Akaike Information Criterion (AIC) and demonstrated with modelled versus observed conditional quantile-quantile (Q-Q) plots.

We next employed conjFDR to identify SNPs jointly associated with MOOD and each psychiatric disorder, which has been described previously in detail (25,31). Briefly, conditional Q-Q plots were constructed to visualise cross-trait polygenic enrichment of SNP associations between MOOD and each psychiatric disorder (*Supplementary methods*). Cross-trait enrichment was leveraged within a Bayesian statistical framework to boost the power to discover shared genetic loci beyond genome-wide significance. Computed as the maximum of two mutual conditional FDR values (*Supplementary methods*), the conjFDR value provides an estimate for the posterior probability that a SNP is not associated with either trait or both traits. SNPs with a conjFDR $<0.05$  were assigned statistical significance.

The consistency of genetic effects in independent samples was evaluated using an *en-masse* sign concordance test (*Supplementary methods*) (32–34).

## Genomic loci definition

Independent genomic loci jointly associated with MOOD and each psychiatric disorder were defined using the FUMA protocol (35). Significant, independent SNPs were defined as conjFDR $<0.05$  and  $r^2<0.6$ . Lead SNPs were chosen if they were in approximate linkage equilibrium with each other ( $r^2<0.1$ ). Transdiagnostic loci were defined as physically overlapping loci which shared at least one candidate SNP with conjFDR $\leq 0.05$  across two or more MOOD/psychiatric disorder conjunctive analyses. Effect directions within transdiagnostic loci were evaluated by comparing effect sizes of the SNP with the lowest maximum conjFDR value within the overlapping region from each MOOD/psychiatric disorder analysis, defined as the “transdiagnostic lead SNP”. LD data was calculated using the European population of the 1000 genomes project reference panel (36).

## Functional annotation

Candidate SNPs, defined as any SNP within each jointly associated genomic locus with a conjFDR value  $<0.10$  and an LD  $r \geq 0.6$  with an independent significant SNP, were functionally annotated using FUMA (35). A lower conjFDR threshold for candidate SNPs was employed to maximise the probability that putative causal SNPs are captured for functional annotation, consistent with previous primary GWAS (33) and conjFDR studies (37). SNPs were mapped to putative causal genes using three strategies: a) positional mapping b) expression quantitative trait locus (eQTL) mapping and c) chromatin interaction mapping(35). We defined a subset of “credible mapped genes” as those that were mapped by all three strategies. We conducted Gene Ontology gene-set analyses using FUMA (35) on credible mapped genes for each MOOD/psychiatric disorder pair. See *Supplementary methods* for further details.

## Data availability

All GWAS summary statistics are publicly available besides 23andMe DEP data (*Supplementary methods*). The code for all analyses can be accessed at <https://github.com/precimed>.

## RESULTS

### Using MiXeR to estimate total polygenic overlap

Univariate MiXeR demonstrated MOOD to be highly polygenic, with 10.4K (SD=0.4K) variants predicted to influence MOOD, comparable to the complex polygenic architectures of psychiatric disorders (*Supplementary table 1, Supplementary figure 1*).


Bivariate MiXeR analysis revealed substantial overlap between MOOD and all four disorders (*Figure 1a, Supplementary table 1*), both in the presence of moderate positive genetic correlation (DEP and ADHD) and minimal genetic correlation (SCZ and BIP). This occurs due to a pattern of mixed effect directions among shared variants, i.e. a balance of variants with concordant and discordant effects on each trait cancel each other out resulting in minimal correlation despite extensive polygenic overlap. For example, the overlap between SCZ and MOOD was particularly striking, with 9.4K (SD=0.4K) shared variants, representing 97% variants influencing SCZ and 90% variants influencing MOOD,

despite weak positive genetic correlation ( $r_g=0.11$ ,  $SE=0.0089$ ). There was also weak positive genetic correlation ( $r_g=0.10$ ,  $SE=0.0096$ ) but fewer shared variants between BIP and MOOD, with 7.8K ( $SD=0.6K$ ) shared variants which represented smaller proportions of trait-influencing variants (91% and 75% for BIP and MOOD respectively). The proportions of shared variants predicted to have concordant effects on MOOD and each of SCZ (54%,  $SD=0.4\%$ ) and BIP (57%,  $SD=0.5\%$ ) were consistent with extensive overlap and weak genetic correlation.

In comparison, DEP ( $r_g=0.62$ ,  $SE=0.011$ ) and ADHD ( $r_g=0.38$ ,  $SE=0.012$ ) possessed stronger positive genetic correlations with MOOD (replicating previous findings in DEP) (18). A total of 7.7K ( $SD=0.3K$ ) variants were estimated to be shared between DEP and MOOD, representing 55% DEP-influencing variants and 74% MOOD-influencing variants. The high number of DEP-specific variants relative to the other disorders (6.3K,  $SD=0.5K$ , 45%) was likely due to DEP's extensive polygenicity (14K,  $SD=0.6K$ ) and may relate to the clinical heterogeneity of the disorder (24,38). ADHD was found to share 4K ( $SD=0.6K$ ) variants, representing 71% ADHD influencing variants and 38% MOOD influencing variants. The high proportion of MOOD-specific variants (6.4K, 0.6K, 62%) is related to ADHD's lower polygenicity (5.6K,  $SD=0.4K$ ) relative to MOOD. Consistent with the stronger positive genetic correlations, there were higher proportions of shared variants predicted to have concordant effects, with 94% ( $SD=2.8\%$ ) concordant for DEP and MOOD and 77% ( $SD=6\%$ ) for ADHD and MOOD. Given the extensive polygenic overlap across phenotypes, we applied the MiXeR model to height and MOOD as a non-psychiatric comparator. MiXeR estimated 0.8K (0.2K) shared variants and minimal negative correlation ( $r_g=-0.08$ ,  $SE=0.0083$ ). AIC and conditional QQ plots to assess MiXeR model fit are described in *Supplementary results*.

The relationship between the number of shared variants and genetic correlation is illustrated in density plots in *Figure 1b*, in which the effect of each variant on MOOD is plotted against its effect on each psychiatric disorder and height. For SCZ and BIP, a large proportion of variants effect both phenotypes (oval) but these are distributed evenly between regions indicating concordant effects (top-right and bottom-left quadrants) and discordant effects (top-left and bottom-right quadrants). The effects of overlapping SNPs cancel each other out leading to weak genetic correlation despite substantial overlap.

For DEP and ADHD, most variants have concordant directions, illustrated by the preponderance of variants in the top-right and bottom-left quadrants. This results in polygenic overlap and stronger positive genetic correlations. The MOOD and height subplot reveals that most variants affecting one trait do not influence the other and vice versa. Almost all associated variants are therefore plotted close to  $\beta=0$  for one or the other phenotype (horizontal and vertical lines), indicating minimal genetic overlap and weak genetic correlation.



**Figure 1:** *a*) Total number of shared variants between mood instability (MOOD, blue) and schizophrenia (SCZ), bipolar disorder (BIP), major depression (DEP), attention-deficit hyperactivity disorder (ADHD) and height as estimated by MiXeR. Venn diagrams representing the proportion of unique and shared variants associated with MOOD and each of SCZ, DEP, BIP, ADHD and height. Polygenic overlap is represented in grey. The numbers indicate the estimated quantity of variants in thousands per component that explains 90% of SNP heritability for each phenotype. The size of the circle reflects the extent of polygenicity for each trait. Genetic correlation ( $r_g$ ) is represented in the horizontal bars beneath the Venn diagrams. Right of the central bar (red) indicates positive  $r_g$  and left of the central bar (blue) indicates negative  $r_g$ . *b*) MiXeR density plots illustrating the effect sizes of variants ( $\beta$ , x and y axes) influencing MOOD and each of SCZ, BIP, DEP, ADHD, and height respectively, with respect to the number of variants (colour scale, blue to yellow). Extensive polygenic overlap of concordant and discordant variants is observed for MOOD and SCZ and BIP. The plots of MOOD and ADHD and DEP also illustrate extensive polygenic overlap, but most variants have concordant effects. The plot of MOOD and height indicates that most variants influencing each trait have little to no effect on the other.



## Identifying genomic loci shared between MOOD and psychiatric disorders

We computed conjFDR values for each SNP present in both primary GWASs. The conjFDR value is interpreted as a conservative estimate for the probability that a given SNP is not associated with either phenotype. By leveraging cross-trait enrichment and employing a Bayesian statistical framework (*Supplementary figures 3-4*), conjFDR identifies jointly associated loci beyond genome-wide significance.

At conjFDR<0.05, MOOD was jointly associated with SCZ at 102 independent genomic loci, BIP at 60 loci, DEP at 163 loci, and ADHD at 28 loci (*Table 1, Supplementary table 2*). Among these, 246 were novel in MOOD, 26 in SCZ, 22 in BIP, 92 in DEP and 12 in ADHD, demonstrating conjFDR's ability to boost the power to discover novel loci. On comparing the effect direction of jointly associated lead SNPs, 58.9% (60/102) were concordant for SCZ and MOOD, 65.0% (39/60) for BIP and MOOD, 96.3% (157/163) for DEP and MOOD and 96% (27/28) for ADHD and MOOD. These figures closely resemble the MiXeR estimates for MOOD and SCZ (54%), BIP (54%) and DEP (94%) but are somewhat discrepant from the estimate for MOOD and ADHD (77%). This is likely due to the small number of loci identified in this analysis. Functional annotation analyses for individual analyses are presented in *Supplementary results*.

## Consistency of genetic effects in independent samples


When comparing the effect directions of lead SNPs in discovery and replication samples, there was significant *en masse* sign concordance for SCZ (74/96 concordant;  $p=4.72e^{-8}$ ), BIP (39/56 concordant;  $p=0.0023$ ) and DEP (121/154 concordant;  $p=2.63e^{-13}$ ). The discrepancy in the number of lead SNPs was due to missing lead SNPs in replication samples (SCZ=6; BIP=4; DEP=9). We did not have access to sufficiently large independent datasets for MOOD or ADHD.

## Identifying and characterising transdiagnostic loci

A total of 53 loci were associated with MOOD and two or more psychiatric disorders (*Supplementary table 9*). Among these, 38 were associated with MOOD and two disorders, 11 with MOOD and three disorders and four with MOOD and all four disorders. Seven transdiagnostic loci had divergent effect directions on psychiatric disorders, but BIP was always concordant with SCZ (n=27) and DEP was always concordant with ADHD (n=18). The distribution of these loci is summarised in *Figure 2*. Loci overlapping across three or more psychiatric disorders are presented in *Table 2*.

Psych	Psych GWAS (n)	Joint loci with MOOD at ( $p < 5 \times 10^{-8}$ )	Joint loci with MOOD at (conjFDR < 0.05)	Novel loci in MOOD (n)	Novel loci in Psych (n)	Replicated loci (sign test) (n)	Transdiagnostic loci (n)
SCZ	105,318	40	102	71	26	74	41
BIP	413,463	5	60	42	22	39	35
DEP	450,619	29	163	140	92	121	38
ADHD	53,293	2	28	17	12	N/a	11

**Table 1:** Summary of the total number of loci jointly associated with mood instability (MOOD) and each of psychiatric disorders (Psych) schizophrenia (SCZ), bipolar disorder (BIP), major depression (DEP) and attention-deficit hyperactivity disorder (ADHD), number of novel loci in each phenotype, number of loci with concordant effect directions in discovery and replication samples, and number of transdiagnostic loci (overlapping between two or more Psych) identified using the conjunctive false discovery rate (conjFDR) method at a threshold of conjFDR < 0.05. The sample sizes of the original Psych GWAS and the number of overlapping loci at genome-wide significance in the original GWAS ( $5 \times 10^{-8}$ ) are provided for comparison.




**Figure 2:** The distribution of transdiagnostic mood instability loci. Venn diagram showing the numbers of diagnosis-specific and transdiagnostic loci across each MOOD and psychiatric disorder conjFDR analysis (SCZ=schizophrenia, BIP= bipolar disorder, DEP=major depression, and ADHD=attention-deficit hyperactivity disorder).

We next identified 1179 genes that were mapped to candidate SNPs from two or more psychiatric disorder/MOOD pairs, 64 of which were mapped by all three strategies (*Supplementary table 7*). *Figure 2* illustrates the chromosomal distribution of the shared loci for each phenotypic pairing alongside mapped genes for each transdiagnostic locus overlapping across three or more disorders. Among these, *VRK2*, *KIAA1109*, *AC110781.3*, *PCLO*, *TMPRSS5* and *EP300* were all mapped to non-synonymous exonic SNPs. Furthermore, *VRK2*, *AC110781.3* and *EP300* were mapped by all three mapping strategies, including eQTLs in the substantia nigra (*VRK2*), caudate, hypothalamus and nucleus accumbens (*AC110781.3*) and the cerebellum and hypothalamus (*EP300*). *VRK2* is a serine threonine kinase which has previously been implicated in SCZ, BIP and DEP and plays a role in neuronal proliferation and migration (39). *AC110781.3* is a gene of unknown function expressed within 13 different brain tissues, with greatest expression in the cortex, amygdala, and hippocampus (*Supplementary figure 5*). It was also mapped to a locus associated with all four disorders, but with opposite effect directions on SCZ and BIP vs DEP and ADHD. Finally, *EP300* is a histone acetyltransferase implicated in cell proliferation and differentiation. Other notable genes mapped to transdiagnostic loci include the dopamine receptor D2 gene (*DRD2*), the calcium channel voltage-gated channel subunit *CACNA1C*, and the neuron specific potassium/chloride transporter *SLC12A5*.

A single gene-set, “Synapse organization” was significantly enriched with mapped genes from all four analyses. There were a further 6 gene-sets enriched with mapped genes for MOOD and each of SCZ, BIP and DEP, although there was extensive overlap in genes across the different gene-sets. All gene-sets besides “Neuron part” were either directly or indirectly related to synaptic structure (“Synapse”, “Synapse part”, “Postsynapse”, “Synaptic membrane”, “cell projection part”) (*Supplementary table 8*). Interestingly, when linking mapped genes from each gene-set back to their associated genomic locus, there was a divergent pattern of effect directions with SCZ (51.4-61.8%) and BIP (58.3-70.6%) showing a pattern of mixed effect directions with MOOD, while DEP (97.4-100%) and ADHD (100%) were almost entirely concordant. This is consistent with the patterns of effect directions estimated by MiXeR and observed in jointly associated loci identified by conjFDR (*Supplementary table 10*). This indicates that the divergent pattern of effect directions persists at the level of specific gene-sets.

Chr	Psych	Min-max BPs	Trans-diagnostic lead SNP	conjFDR	Concordant effects	Novel in Psych	Novel in MOOD	Mapped genes
2	SCZ	22430795-22545027	rs13387284	0.029	TRUE	x	TRUE	<i>AC068490.2<sup>a</sup></i>
	BIP	22430795-22606275		0.035	TRUE	x		
	DEP	22430795-22606275		0.010	TRUE	x		
	ADHD	22430795-22493637		0.029	TRUE	x		
2	SCZ	57942987-58505679	rs2717039	0.029	TRUE	x	x	<b><i>VRK2, FANCL, BCL11A</i></b>
	BIP	57956088-58444610		0.032	TRUE	x		
	DEP	57942987-58484172		0.010	TRUE	x		
4	SCZ	122913532-123558330	rs10014468	0.019	x	x	x	<i>TRPC3, KIAA1109, IL21</i>
	BIP	123026869-123558330		0.0048	x	x		
	DEP	123052343-123558330		0.0015	TRUE	x		
5	SCZ	103791044-104055261	rs2447832	0.044	TRUE	x	x	<i>RP11-6N13.<sup>a</sup>, CTD-2374C24.1<sup>a</sup></i>
	BIP	103671867-104082179		0.036	TRUE	x		
	DEP	103671867-104082179		0.013	TRUE	x		
	ADHD	103671867-104082179		0.033	TRUE	x		
7	SCZ	1873756-2110850	rs55790766	0.026	x	x	x	<b><i>AC110781.3, INTS1, MAFK, TMEM184A, PSMG3, ELFN1, MAD1L1, FTSJ2, NUDT1</i></b>
	BIP	1882795-2110850		0.011	x	x		
	DEP	1860733-2247403		0.005	TRUE	x		
	ADHD	1873756-2110850		0.037	TRUE	x		
7	SCZ	82386297-82641937	rs2158220	0.006	TRUE	x	TRUE	<i>HGF, PCLO</i>
	BIP	82376952-82555669		0.01	TRUE	x		
	DEP	82386297-82557937		0.012	TRUE	x		
8	SCZ	8088230-11417790	rs2952245	0.028	x	x	x	<b><i>MRSA<sup>c</sup></i></b>
	BIP	7632319-11830150		0.044	x	x		
	DEP	10121605-10435915		0.036	TRUE	x		
10	SCZ	106453832-106640653	rs2496014	0.016	TRUE	x	x	<i>SORCS3</i>
	BIP	106455520-106640653		0.022	TRUE	x		
	DEP	106405854-106830537		0.006	TRUE	x		
	ADHD	106392549-106640653		0.016	TRUE	x		
11	SCZ	113185591-113692660	rs2514218	7.37e <sup>-7</sup>	TRUE	x	x	<b><i>TTC12, DRD2, AP002884.3, BCO2, PLET1, AP002884.2, TMPRSS5, ZBTB16</i></b>
	BIP	113241877-113451229		0.001	TRUE	x		
	DEP	113166310-113692660		0.0015	TRUE	x		
12	SCZ	2474661-2523772	rs2239063	0.038	TRUE	x	TRUE	<i>CACNA1C</i>
	BIP	2474661-2523772		0.043	TRUE	x		
	DEP	2465364-2523772		0.016	TRUE	x		
18 <sup>b</sup>	SCZ	50517509-51055069	rs1367635	0.0032	TRUE	x	x	<i>DCC</i>
	BIP	50711776-50907127		0.034	TRUE	x		
	DEP	50358109-51055069		0.0035	TRUE	x		
18 <sup>b</sup>	SCZ	50517509-51055069	rs7506904	0.049	TRUE	x	x	<i>DCC</i>
	DEP	50197439-51055069		0.048	TRUE	x		
	ADHD	50358109-51055069		0.046	TRUE	x		
18	SCZ	52720948-53474904	rs4505420	0.0032	TRUE	x	x	<i>RAB27B, TXNLI, WDR7</i>
	BIP	52720948-52827668		0.0083	TRUE	TRUE		
	DEP	52520149-53424880		0.0098	TRUE	x		
20	SCZ	44680853-44749251	rs6032660	0.044	TRUE	TRUE	x	<b><i>SLC12A5, CD40, UBE2C, ZSWIM1, SPATA25, NEURL2, CTSA, PCIF1, AL162458.1, NCOA5, ELMO2</i></b>
	BIP	44680412-44747947		0.047	TRUE	x		
	ADHD	44680853-44749251		0.042	TRUE	x		
22	SCZ	41080566-42248289	rs80533	0.01	TRUE	x	x	<b><i>MCHR1, SLC25A17, XPNPEP3, RBX1, EP300, L3MBTL2, RANGAPI, ZC3H7B, SGSM3, TOB2, PHF5A, ACO2, POLR3H, MEI1, WBP2NL</i></b>
	BIP	41080566-41404511		0.021	TRUE	x		
	DEP	41080566-42216326		0.0067	TRUE	x		

**Table 2:** Transdiagnostic loci jointly associated with mood instability (MOOD) and psychiatric disorders (Psych) across three or more disorders. Minimum and maximum base pairs (BPs), “transdiagnostic lead SNPs” and conjunctive false discovery statistics (conjFDR) are presented for each locus. The concordance of effect direction and novelty of a locus for MOOD and each Psych is indicated by “TRUE”. Protein-coding genes mapped to candidate SNPs from each MOOD/Psych analysis are presented. If there were no protein-coding genes mapped to a locus, non-protein coding mapped genes are presented (<sup>a</sup>). Genes mapped by all three mapping strategies (credible genes) are in bold. <sup>b</sup>Loci are physically overlapping but there was no candidate SNP with conjFDR<0.05 across all four analyses. Locus spans 8p23 inversion region with complex linkage disequilibrium. This biases gene-mapping strategies so only a single mapped gene is presented.



**Figure 3:** Manhattan plot showing  $-\log_{10}$  transformed conjunctural FDR (conjFDR) values for mood instability (MOOD) and *a*) schizophrenia (SCZ, blue) *b*) bipolar disorder (BIP, orange) *c*) major depression (DEP, green) and *d*) attention-deficit hyperactivity disorder (ADHD, red) for each SNP (y axis) against chromosomal position (x axis). The dotted line represents  $\text{conjFDR} < 0.05$  significance threshold. Black circles represent lead SNPs. Lead SNPs from transdiagnostic loci across three or more disorders are annotated with mapped genes. N.B. Not all mapped genes for each locus are presented due to space limitations. Credible genes (bold) were prioritised followed by protein-coding genes and then non-protein-coding genes. \* Locus spans 8p23 inversion region with complex linkage disequilibrium. This biases gene-mapping strategies so only a single mapped gene is presented.

## DISCUSSION

In this combined GWAS analysis, we used MiXeR to reveal extensive polygenic overlap between MOOD and each of SCZ, BIP, DEP and ADHD despite divergent patterns of genetic correlations. A large proportion of the genetic variants linked to psychiatric disorders also influence MOOD, but the number of shared and trait specific variants and the balance of protective and risk-enhancing variants differ across diagnostic groups. Using conjFDR, MOOD was jointly associated with SCZ at 163 loci, BIP at 60 loci, DEP at 163 loci and ADHD at 28 loci, representing 259 unique genomic loci jointly associated with MOOD and psychiatric disorders. Of these, 220 were novel in MOOD and 152 were novel in psychiatric disorders. Replication analysis provided evidence of consistent genetic effects in independent SCZ, BIP and DEP samples. We identified 53 transdiagnostic loci that were overlapping across MOOD and two or more psychiatric disorders, implicating 1179 putative transdiagnostic genes with an apparent convergence on synaptic gene-sets, although a divergent pattern of effect directions persisted within shared gene-sets. These findings have implications for how the genetic risk of mental-health related traits is conceptualized and suggests differences in the neurobiological basis of MOOD across different psychiatric disorders, including the possibility of genetically influenced sub-groups of patients with more or less prominent MOOD. We also highlight genes that are likely to influence MOOD across several diagnoses, indicating high relevance for future *in vitro* and *in vivo* investigation. Firstly, 55%-97% of disorder associated variants were predicted to influence MOOD, raising questions about the specificity of the genetic architecture of these complex polygenic psychiatric disorders and related traits. Our findings compliment evidence that a large proportion of genetic variants are not unique for a given mental trait or disorder (26,40), but influence multiple mental phenotypes to different degrees. As such, the distinct SNP-based risk profiles for different mental-health related traits are not merely defined by unique non-overlapping sets of genetic variants, but largely accounted for by a set of pleiotropic non-specific genetic variants showing different strengths of association and effect across these phenotypes (26). Although this hypothesis warrants further interrogation, it suggests that novel approaches are needed to account for the substantial pleiotropy we predict in order to robustly distinguish the genetic risk for different mental traits and disorders.<sup>26</sup> Furthermore, this places emphasis

on identifying disease specific variants that may disproportionately affect the development of a specific phenotype, individually and/or collectively, to inform precision medicine approaches in psychiatry.

Secondly, MOOD has gained interest due to its prevalence across diagnoses and its prominent neurobiological basis (14), implying that it may represent a novel treatment target (2,14). To some extent, this is supported by the large degree of shared genomic loci and corresponding mapped genes identified. However, there were differences in genetic correlations and effect directions of shared loci, with stronger positive correlations and higher proportions of loci with concordant effects in DEP and ADHD compared to weak correlations and lower proportions of loci with concordant effects in SCZ and BIP. This pattern persisted within specific gene-sets identified across multiple analyses. This implies that there may be mechanistic differences in MOOD across the four psychiatric disorders. It is important to note that this measure only reflects one aspect of MOOD, which may explain the lack of correlation with SCZ and BIP, particularly given MOOD's strong clinical association with BIP. Nonetheless, it is tempting to speculate that MOOD experienced in DEP and ADHD has a similar neurobiological relationship whereas MOOD in BIP and SCZ may reflect a different underlying aetiological mechanism. This is relevant as such differences may limit the potential for transdiagnostic pharmacological interventions. Alternatively, the current findings are also consistent with subgroups characterised by higher or lower MOOD within diagnostic categories, in line with clinical observations (41). Above all, these findings emphasise the importance of exploring the neurobiological and phenomenological differences in MOOD across diagnostic groups.

To characterise MOOD's neurobiological underpinnings, we used three gene-mapping strategies to identify credible mapped genes for all jointly associated loci. Among these, *AC110781.3* was mapped to a non-synonymous exonic SNP jointly associated with MOOD and all four psychiatric disorders. *AC110781.3* is a protein-coding gene of unknown function that is expressed in the cortex, amygdala and hippocampus. In addition to previously being implicated in schizophrenia (42) and risk-taking behaviour (43), we also recently linked *AC110781.3* to multiple sleep phenotypes and BIP, DEP and SCZ in an analysis of the genetic overlap between sleep-related phenotypes and psychiatric disorders. This suggests *AC110781.3* influences multiple diverse phenotypes and may represent a promising

candidate for further *in vitro* and *in vivo* investigation. We also identified several well-established psychiatric risk genes, including *VRK2* (39), *CACNA1C* (44), and *DRD2* (45), although an association with mood instability has not previously been described in the literature. The convergence of transdiagnostic mapped genes on synaptic structure builds on *Ward et al.*'s finding in the primary mood instability GWAS that mapped genes were associated with synaptic transmission.

Finally, while mood instability has a prominent genetic component, it remains influenced by environmental factors (12,18). Future work focusing on gene-environmental interplay, particularly in relation to childhood trauma which has been found to correlate with the development of mood instability (46), would be of high interest.

There were limitations to the current study. Firstly, due to available sample sizes and multi-ancestral differences in LD structure we were unable to include multi-ancestral samples. This is an essential area for improvement in psychiatric genetics. Secondly, due to the small sample size of the most recent borderline personality disorder GWAS ( $n=2\ 579$ ), we were unable to include it in the current analysis despite its primacy in MOOD (2). This analysis should be repeated as sample sizes increase to include other relevant disorders, identify more transdiagnostic loci, and validate MiXeR's predictions. Thirdly, the measure of MOOD was based on a single, binary questionnaire item that did not measure affect intensity, regulation of affect or behavioural sequelae, and did not specify the timeframe (1). This may have contributed to the lack of genetic correlations with SCZ and BIP. Nonetheless, a simple measure was necessary to achieve a large enough sample size to achieve a genome-wide signal. Previous GWAS using more complete measures have substantially smaller sample sizes and failed to identify genome-wide significant loci (47). Moreover, the same binary questionnaire item is associated with BIP and DEP, demonstrating its clinical relevance. Future work with more refined measures is required to understand how these findings relate to other dimensions of MOOD. Finally, differences in sample size affect conjFDR's power to discover shared loci. This precludes cross-analysis comparisons of the number of loci discovered by conjFDR. The disparity between the number of shared loci discovered and the number of shared variants predicted by MiXeR also indicates that we cannot confidently identify loci "unique" to each mental disorder, since it is possible that the lack of association is due to type II



error. This will only be addressed once larger proportions of disorder-influencing variants have been discovered.

In conclusion, we have discovered extensive polygenic overlap between MOOD and psychiatric disorders with divergent patterns of genetic correlation and effect directions. These results support the notion that there are common molecular pathways implicated in MOOD across diagnostic categories, but disorder specific effect size distributions indicate key differences in MOOD's neurobiological underpinnings across diagnoses.

## ACKNOWLEDGEMENTS

We would like to thank Dr. Yunhan Chu for her thoughtful contributions to the manuscript. We thank the research participants and employees of the Schizophrenia, Depression and Bipolar Disorder Working Groups of the Psychiatric Genomics Consortium, 23andMe, UK Biobank, and FinnGen for making this research possible. We gratefully acknowledge support from the American National Institutes of Health (NS057198, EB00790), the Research Council of Norway (229129, 213837, 223273), the South-East Norway Regional Health Authority (2017-112), KG Jebsen Stiftelsen (SKGJ-MED-008) and the PGC US Norway Collaboration (RCN# 248980). This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 847776. This research has been conducted using data from UK Biobank, a major biomedical database (Project ID number 27412; [www.ukbiobank.ac.uk](http://www.ukbiobank.ac.uk)).

## DISCLOSURES

O.A.A. has received speaker's honorarium from Lundbeck and is a consultant for Healthlytix. A.M.D. is a founder of and holds equity interest in CorTechs Labs and serves on its scientific advisory board. He is also a member of the Scientific Advisory Board of Healthlytix and receives research funding from General Electric Healthcare (GEHC). The terms of these arrangements have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. Remaining authors report no financial relationships with commercial interests.

## REFERENCES

1. Marwaha S, He Z, Broome M, Singh SP, Scott J, Eyden J, Wolke D (2014): How is affective instability defined and measured? A systematic review. *Psychol Med* 44: 1793–1808.
2. Koenigsberg HW (2010): Affective instability: Toward an integration of neuroscience and psychological perspectives. *J Pers Disord* 24: 60–82.
3. Marwaha S, Parsons N, Flanagan S, Broome M (2013): The prevalence and clinical associations of mood instability in adults living in England: Results from the Adult Psychiatric Morbidity Survey 2007. *Psychiatry Res* 205: 262–268.
4. Patel R, Lloyd T, Jackson R, Ball M, Shetty H, Broadbent M, *et al.* (2015): Mood instability is a common feature of mental health disorders and is associated with poor clinical outcomes. *BMJ Open* 5. <https://doi.org/10.1136/bmjopen-2014-007504>
5. Høegh MC, Melle I, Aminoff SR, Laskemoen JF, Büchmann CB, Ueland T, Lagerberg TV (2020): Affective lability across psychosis spectrum disorders. *Eur Psychiatry* 1–17.
6. Thompson RJ, Berenbaum H, Bredemeier K (2011): Cross-sectional and longitudinal relations between affective instability and depression. *J Affect Disord* 130: 53–59.
7. Skirrow C, McLoughlin G, Kuntsi J, Asherson P (2009): Behavioral, neurocognitive and treatment overlap between attention-deficit/hyperactivity disorder and mood instability. *Expert Rev Neurother* 9: 489–503.
8. Angst J, Gamma A, Endrass J (2003): Risk factors for the bipolar and depression spectra. *Acta Psychiatr Scand* 108: 15–19.
9. Bonsall MB, Wallace-Hadrill SMA, Geddes JR, Goodwin GM, Holmes EA (2012): Nonlinear time-series approaches in characterizing mood stability and mood instability in bipolar disorder. *Proc R Soc B Biol Sci* 279: 916–924.
10. Henry C, Van den Bulke D, Bellivier F, Roy I, Swendsen J, M'Baïlara K, *et al.* (2008): Affective lability and affect intensity as core dimensions of bipolar disorders during euthymic period. *Psychiatry Res* 159: 1–6.
11. Marwaha S, Parsons N, Broome M (2013): Mood instability, mental illness and suicidal ideas: Results from a household survey. *Soc Psychiatry Psychiatr Epidemiol* 48: 1431–1437.
12. Coccaro EF, Ong AD, Seroczynski AD, Bergeman CS (2012): Affective intensity and lability: heritability in adult male twins. *J Affect Disord* 136: 1011–1016.
13. Price TRP, Goetz KL, Lovell MR (2011): Brain tumors. *Clinical Manual of Neuropsychiatry*. American Psychiatric Press USA, pp 235–263.
14. Broome MR, He Z, Iftikhar M, Eyden J, Marwaha S (2015): Neurobiological and behavioural studies of affective instability in clinical populations: A systematic review. *Neurosci Biobehav Rev* 51: 243–254.
15. Harrison PJ, Geddes JR, Tunbridge EM (2018): The Emerging Neurobiology of Bipolar Disorder, 2017/11/20. *Trends Neurosci* 41: 18–30.
16. Das P, Calhoun V, Malhi GS (2014): Bipolar and borderline patients display differential patterns of functional connectivity among resting state networks. *Neuroimage* 98: 73–81.
17. Ward J, Strawbridge RJ, Bailey MES, Graham N, Ferguson A, Lyall DM, *et al.* (2017): Genome-wide analysis in UK Biobank identifies four loci associated with mood instability and genetic correlation with major depressive disorder, anxiety disorder and schizophrenia. *Transl Psychiatry* 7: 1264.
18. Ward J, Tunbridge EM, Sandor C, Lyall LM, Ferguson A, Strawbridge RJ, *et al.* (2019): The genomic basis of mood instability: identification of 46 loci in 363,705 UK Biobank participants,

- genetic correlation with psychiatric disorders, and association with gene expression and function. *Mol Psychiatry* 1–9.
19. Pardiñas AF, Holmans P, Pocklington AJ, Escott-Price V, Ripke S, Carrera N, *et al.* (2018): Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. *Nat Genet* 50: 381–389.
  20. Stahl EA, Breen G, Forstner AJ, McQuillin A, Ripke S, Trubetskoy V, *et al.* (2019): Genome-wide association study identifies 30 loci associated with bipolar disorder. *Nat Genet* 51: 793–803.
  21. Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, *et al.* (2018): Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. *Nat Genet* 50: 668.
  22. Girard SL, Xiong L, Dion PA, Rouleau GA (2011): Where are the missing pieces of the schizophrenia genetics puzzle? *Curr Opin Genet Dev* 21: 310–316.
  23. Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, *et al.* (2019): Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. *Nat Genet* 51: 63–75.
  24. Frei O, Holland D, Smeland OB, Shadrin AA, Fan CC, Maeland S, *et al.* (2019): Bivariate causal mixture model quantifies polygenic overlap between complex traits beyond genetic correlation. *Nat Commun* 10: 1–11.
  25. Smeland OB, Frei O, Shadrin A, O’Connell K, Fan C-C, Bahrami S, *et al.* (2019): Discovery of shared genomic loci using the conditional false discovery rate approach. *Hum Genet* 1–10.
  26. Smeland OB, Frei O, Dale AM, Andreassen OA (2020): The polygenic architecture of schizophrenia — rethinking pathogenesis and nosology. *Nature Reviews Neurology*. Nature Research, pp 1–14.
  27. Mullins N, Forstner AJ, O’Connell KS, Coombes B, Coleman JRI, Qiao Z, *et al.* (2021): Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. *Nat Genet*. <https://doi.org/10.1038/s41588-021-00857-4>
  28. Yengo L, Sidorenko J, Kemper KE, Zheng Z, Wood AR, Weedon MN, *et al.* (2018): Meta-analysis of genome-wide association studies for height and body mass index in ~700000 individuals of European ancestry. *Hum Mol Genet* 27: 3641–3649.
  29. Lam M, Chen CY, Li Z, Martin AR, Bryois J, Ma X, *et al.* (2019): Comparative genetic architectures of schizophrenia in East Asian and European populations. *Nat Genet* 51: 1670–1678.
  30. FinnGen (2020): FinnGen Documentation of R4 release. Retrieved January 27, 2021, from <https://finngen.gitbook.io/documentation/>
  31. Andreassen OA, Harbo HF, Wang Y, Thompson WK, Schork AJ, Mattingsdal M, *et al.* (2015): Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci, 2014/01/28. *Mol Psychiatry* 20: 207–214.
  32. Ripke S, Walters JTR, O’Donovan MC (2020): Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia. *medRxiv* 2020.09.12.20192922.
  33. Lee JJ, Wedow R, Okbay A, Kong E, Maghzian O, Zacher M, *et al.* (2018): Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. *Nat Genet* 50: 1112–1121.
  34. Savage JE, Jansen PR, Stringer S, Watanabe K, Bryois J, De Leeuw CA, *et al.* (2018): Genome-wide association meta-analysis in 269,867 individuals identifies new genetic and functional links to intelligence. *Nat Genet* 50: 912–919.
  35. Watanabe K, Taskesen E, van Bochoven A, Posthuma D (2017): Functional mapping and annotation of genetic associations with FUMA. *Nat Commun* 8: 1826.
  36. Auton A, Abecasis GR, Altshuler DM, Durbin RM, Bentley DR, Chakravarti A, *et al.* (2015): A

- global reference for human genetic variation. *Nature* 526: 68–74.
37. Bahrami S, Shadrin A, Frei O, O’Connell KS, Bettella F, Krull F, *et al.* (2021): Genetic loci shared between major depression and intelligence with mixed directions of effect. *Nat Hum Behav* 1–7.
  38. Holland D, Frei O, Desikan R, Fan C-C, Shadrin AA, Smeland OB, *et al.* (2020): Beyond SNP heritability: Polygenicity and discoverability of phenotypes estimated with a univariate Gaussian mixture model (X. Zhu, editor). *PLOS Genet* 16: e1008612.
  39. Li M, Yue W (2018): **VRK2**, a Candidate Gene for Psychiatric and Neurological Disorders. *Mol Neuropsychiatry* 4: 119–133.
  40. Smeland OB, Frei O, Fan CC, Shadrin A, Dale AM, Andreassen OA (2020): The emerging pattern of shared polygenic architecture of psychiatric disorders, conceptual and methodological challenges. *Psychiatric Genetics*, vol. 29. Lippincott Williams and Wilkins, pp 152–159.
  41. Ducasse D, Jaussent I, Guillaume S, Azorin JM, Bellivier F, Belzeaux R, *et al.* (2017): Affect lability predicts occurrence of suicidal ideation in bipolar patients: a two-year prospective study. *Acta Psychiatr Scand* 135: 460–469.
  42. Huckins LM, Dobbyn A, Ruderfer DM, Hoffman G, Wang W, Pardiñas AF, *et al.* (2019): Gene expression imputation across multiple brain regions provides insights into schizophrenia risk. *Nat Genet* 51: 659–674.
  43. Karlsson Linnér R, Biroli P, Kong E, Meddens SFW, Wedow R, Fontana MA, *et al.* (2019): Genome-wide association analyses of risk tolerance and risky behaviors in over 1 million individuals identify hundreds of loci and shared genetic influences. *Nat Genet* 51: 245–257.
  44. Moon AL, Haan N, Wilkinson LS, Thomas KL, Hall J (2018): CACNA1C: Association with psychiatric disorders, behavior, and neurogenesis. *Schizophr Bull* 44: 958–965.
  45. Psychiatric SWG of the, Ripke S, Neale BM, Corvin A, Walters JTR, Farh K-H, *et al.* (2014): Biological insights from 108 schizophrenia-associated genetic loci. *Nature* 511: 421.
  46. Marwaha S, Gordon-Smith K, Broome M, Briley PM, Perry A, Forty L, *et al.* (2016): Affective instability, childhood trauma and major affective disorders. *J Affect Disord* 190: 764–771.
  47. Gisbert L, Vilar L, Rovira P, Sánchez-Mora C, Payerols M, Garcia-Martínez I, *et al.* (2019): Genome-wide analysis of emotional lability in adult attention deficit hyperactivity disorder (ADHD). *Eur Neuropsychopharmacol* 29: 795–802.